Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC

NCT07733830 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Adebrelimab
DRUG: Nab paclitaxel
DRUG: Carboplatin
RADIATION: radiation

Sponsor

Tianjin Medical University Cancer Institute and Hospital